209 related articles for article (PubMed ID: 36275733)
1. The established chemokine-related prognostic gene signature in prostate cancer: Implications for anti-androgen and immunotherapies.
Chen L; Zheng Y; Jiang C; Yang C; Zhang L; Liang C
Front Immunol; 2022; 13():1009634. PubMed ID: 36275733
[TBL] [Abstract][Full Text] [Related]
2. The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma.
Gu CY; Dai B; Zhu Y; Lin GW; Wang HK; Ye DW; Qin XJ
Mol Med; 2022 Jul; 28(1):78. PubMed ID: 35836112
[TBL] [Abstract][Full Text] [Related]
3. Biochemical recurrence related metabolic novel signature associates with immunity and ADT treatment responses in prostate cancer.
Wang X; Lv Z; Xia H; Guo X; Wang J; Wang J; Liu M
Cancer Med; 2023 Jan; 12(1):862-878. PubMed ID: 35681277
[TBL] [Abstract][Full Text] [Related]
4. Identification of bicalutamide resistance-related genes and prognosis prediction in patients with prostate cancer.
Li Y; Wang H; Pan Y; Wang S; Zhang Z; Zhou H; Xu M; Liu X
Front Endocrinol (Lausanne); 2023; 14():1125299. PubMed ID: 37143720
[TBL] [Abstract][Full Text] [Related]
5. Identification and validation of an E2F-related gene signature for predicting recurrence-free survival in human prostate cancer.
Yang C; Chen L; Niu Q; Ge Q; Zhang J; Tao J; Zhou J; Liang C
Cancer Cell Int; 2022 Dec; 22(1):382. PubMed ID: 36471446
[TBL] [Abstract][Full Text] [Related]
6. A novel 13 RNA binding proteins (RBPs) signature could predict prostate cancer biochemical recurrence.
Xing Q; Liu S; Luan J; Wang Y; Ma L
Pathol Res Pract; 2021 Sep; 225():153587. PubMed ID: 34419719
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of novel inflammatory response-related gene signature to predict prostate cancer recurrence and response to immune checkpoint therapy.
Luo Y; Liu X; Lin J; Zhong W; Chen Q
Math Biosci Eng; 2022 Aug; 19(11):11345-11366. PubMed ID: 36124593
[TBL] [Abstract][Full Text] [Related]
8. Integrative multi-omics analysis unveils stemness-associated molecular subtypes in prostate cancer and pan-cancer: prognostic and therapeutic significance.
Zheng K; Hai Y; Xi Y; Zhang Y; Liu Z; Chen W; Hu X; Zou X; Hao J
J Transl Med; 2023 Nov; 21(1):789. PubMed ID: 37936202
[TBL] [Abstract][Full Text] [Related]
9. Alzheimer Gene BIN1 may Simultaneously Influence Dementia Risk and Androgen Deprivation Therapy Dosage in Prostate Cancer.
Lehrer S; Rheinstein PH
Am J Clin Oncol; 2020 Oct; 43(10):685-689. PubMed ID: 32568785
[TBL] [Abstract][Full Text] [Related]
10. A prognostic signature consisting of N6-methyladenosine modified mRNAs demonstrates clinical potential in prediction of biochemical recurrence and guidance on precision therapy in prostate cancer.
Lu J; Chen J; Lin Z; Liu Q; Zhong C; Cai Z; Jia Z; Zhong W; Liang Y; Cai C
Transl Oncol; 2023 Jul; 33():101670. PubMed ID: 37060728
[TBL] [Abstract][Full Text] [Related]
11. A novel ferroptosis-related gene prognostic index for prognosis and response to immunotherapy in patients with prostate cancer.
Wang Y; Fan J; Chen T; Xu L; Liu P; Xiao L; Wu T; Zhou Q; Zheng Q; Liu C; Chan FL; Wu D
Front Endocrinol (Lausanne); 2022; 13():975623. PubMed ID: 36034466
[TBL] [Abstract][Full Text] [Related]
12. Integrating single-cell and bulk RNA sequencing to predict prognosis and immunotherapy response in prostate cancer.
Wen XY; Wang RY; Yu B; Yang Y; Yang J; Zhang HC
Sci Rep; 2023 Sep; 13(1):15597. PubMed ID: 37730847
[TBL] [Abstract][Full Text] [Related]
13. The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy.
Huang KC; Alshalalfa M; Hegazy SA; Dolph M; Donnelly B; Bismar TA
Cancer Biol Ther; 2014 Sep; 15(9):1120-8. PubMed ID: 24972028
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of the biological functions of endoplasmic reticulum stress in prostate cancer.
Cen S; Jiang D; Lv D; Xu R; Hou J; Yang Z; Wu P; Xiong X; Gao X
Front Endocrinol (Lausanne); 2023; 14():1090277. PubMed ID: 36967783
[TBL] [Abstract][Full Text] [Related]
15. Establishment of an age- and tumor microenvironment-related gene signature for survival prediction in prostate cancer.
Chen L; Zhang M; Zhou J; Zhang L; Liang C
Cancer Med; 2022 Nov; 11(22):4374-4388. PubMed ID: 35535438
[TBL] [Abstract][Full Text] [Related]
16. Construction and validation of a fatty acid metabolism-related gene signature for predicting prognosis and therapeutic response in patients with prostate cancer.
Zhao H; Wu T; Luo Z; Huang Q; Zhu S; Li C; Zhang Z; Zhang J; Zeng J; Zhang Y
PeerJ; 2023; 11():e14854. PubMed ID: 36778142
[TBL] [Abstract][Full Text] [Related]
17. Construction of a risk prediction model using m6A RNA methylation regulators in prostate cancer: comprehensive bioinformatic analysis and histological validation.
Quan Y; Zhang X; Ping H
Cancer Cell Int; 2022 Jan; 22(1):33. PubMed ID: 35045837
[TBL] [Abstract][Full Text] [Related]
18. Immune signature driven by ADT-induced immune microenvironment remodeling in prostate cancer is correlated with recurrence-free survival and immune infiltration.
Long X; Hou H; Wang X; Liu S; Diao T; Lai S; Hu M; Zhang S; Liu M; Zhang H
Cell Death Dis; 2020 Sep; 11(9):779. PubMed ID: 32951005
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy.
Geybels MS; Wright JL; Bibikova M; Klotzle B; Fan JB; Zhao S; Feng Z; Ostrander EA; Lin DW; Nelson PS; Stanford JL
Clin Epigenetics; 2016; 8():97. PubMed ID: 27651837
[TBL] [Abstract][Full Text] [Related]
20. Integrated machine learning identifies epithelial cell marker genes for improving outcomes and immunotherapy in prostate cancer.
Zhu W; Zeng H; Huang J; Wu J; Wang Y; Wang Z; Wang H; Luo Y; Lai W
J Transl Med; 2023 Nov; 21(1):782. PubMed ID: 37925432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
